{"id":939428,"date":"2026-02-24T08:29:56","date_gmt":"2026-02-24T13:29:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/"},"modified":"2026-02-24T08:29:56","modified_gmt":"2026-02-24T13:29:56","slug":"holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/","title":{"rendered":"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ATLANTA, Feb.  24, 2026  (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (\u201cVistagen\u201d or the \u201cCompany\u201d) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and\/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen\u2019s Phase 3 PALISADE-3 trial study of fasedienol.<\/p>\n<p align=\"justify\">If you purchased Vistagen shares between <strong>April 1, 2024 and December 16, 2025<\/strong>, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I3IRoZY76HDssynd20IQnRGNROwOnY5NZNKNh5uET784w1aMMYM0_Y_NZqNrlu9dFORlCrfq2ftmOwUmfIG3rG9TKxl0opmohXMPvmS6gC0=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a>, by toll-free telephone at (888) 508-6832, or by visiting the firm\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qlqnMX9zbXTxLhyJLDrzMHGYM79rnidzHIIfPY0bqsbIdmHmypz6Danq3DMiy0-aUPq5x_COE7jHcUxNKDDGSlPW4zp1jQR9Elt4EsGsFyUVp6T7xgQLE05vi2MEaxHTvZ2vuXqgTFtvtsmNxE27n-1ZY1o2MwswJGkHQl0xoeM=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com\/case\/vistagen-therapeutics\/<\/a> for more information.<\/p>\n<p align=\"justify\">\n        <strong>The deadline to ask the court to be appointed lead plaintiff in the case is\u00a0March 16, 2026.<\/strong>\n      <\/p>\n<p align=\"justify\">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.\u202fMore information about the firm is available through its website,\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qlqnMX9zbXTxLhyJLDrzMBOxpumBuSHv7CIHbkGeP92b1_aDSsG7ZLms9zNeQXGdaBfmaBKWs5SZZ-qB2-Dj0y_2vh0zBirN8KZPXDSlY4Y=\" rel=\"nofollow\" target=\"_blank\">www.holzerlaw.com<\/a>,\u202fand upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.\u202f\u00a0<\/p>\n<p align=\"justify\">CONTACT:<br \/>Corey Holzer, Esq.<br \/>(888) 508-6832 (toll-free) <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I3IRoZY76HDssynd20IQnRGNROwOnY5NZNKNh5uET7_SmIEawAQJKdsbpFaiMJoi6VFaGv4hX_WUMeF_WQ5RERkoPGQYWBDnDgEyqhP52Dg=\" rel=\"nofollow\" target=\"_blank\">cholzer@holzerlaw.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2M2NGQ3YjAtMzQwNS00YTcxLThkNTktOGJlM2E3ZmJjN2I4LTExOTIzMzYtMjAyNi0wMi0yNC1lbg==\/tiny\/Holzer-Holzer.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (\u201cVistagen\u201d or the \u201cCompany\u201d) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and\/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen\u2019s Phase 3 PALISADE-3 trial study of fasedienol. If you purchased Vistagen shares between April 1, 2024 and December 16, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm\u2019s website at www.holzerlaw.com\/case\/vistagen-therapeutics\/ for more information. The deadline to ask the court to be appointed &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-939428","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (\u201cVistagen\u201d or the \u201cCompany\u201d) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and\/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen\u2019s Phase 3 PALISADE-3 trial study of fasedienol. If you purchased Vistagen shares between April 1, 2024 and December 16, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm\u2019s website at www.holzerlaw.com\/case\/vistagen-therapeutics\/ for more information. The deadline to ask the court to be appointed &hellip; Continue reading &quot;Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T13:29:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action\",\"datePublished\":\"2026-02-24T13:29:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/\"},\"wordCount\":262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/\",\"name\":\"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=\",\"datePublished\":\"2026-02-24T13:29:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/","og_locale":"en_US","og_type":"article","og_title":"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action - Market Newsdesk","og_description":"ATLANTA, Feb. 24, 2026 (GLOBE NEWSWIRE) &#8212; A shareholder class action lawsuit has been filed against Vistagen Therapeutics, Inc. (\u201cVistagen\u201d or the \u201cCompany\u201d) (NASDAQ: VTGN). The lawsuit alleges that Defendants issued false and misleading statements and\/or failed to disclose material adverse facts regarding the risks of failure associated with Vistagen\u2019s Phase 3 PALISADE-3 trial study of fasedienol. If you purchased Vistagen shares between April 1, 2024 and December 16, 2025, and experienced a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm\u2019s website at www.holzerlaw.com\/case\/vistagen-therapeutics\/ for more information. The deadline to ask the court to be appointed &hellip; Continue reading \"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-24T13:29:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action","datePublished":"2026-02-24T13:29:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/"},"wordCount":262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/","name":"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=","datePublished":"2026-02-24T13:29:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1OTg3MSM3NDQ5ODAzIzIxODA3Njc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/holzer-holzer-llc-reminds-vtgn-investors-of-the-march-16-2026-lead-plaintiff-deadline-in-the-vistagen-therapeutics-inc-securities-class-action-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Holzer &amp; Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the\u00a0Vistagen Therapeutics, Inc. Securities Class Action"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939428","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=939428"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/939428\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=939428"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=939428"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=939428"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}